Comparing the current results to its competitors, Verona Pharma Plc reported Revenue increase in the 2 quarter 2025 by 0 % year on year. The revenue growth was below Verona Pharma Plc's competitors' average revenue growth of 10.24 %, achieved in the same quarter.
Verona Pharma Plc's Comment on Competition and Industry Peers
Ohtuvayre is positioned to compete with approved COPD therapies, including nebulized and handheld inhaler formulations such as dry powder inhalers (DPI) and pressurized metered-dose inhalers (pMDI). Ensifentrine's competitors in the U.S. nebulizer market for COPD maintenance treatment include the long-acting beta2-agonists (LABAs) Brovana and Perforomist, and the long-acting muscarinic antagonist (LAMA) Yupelri. In the DPI and pMDI markets, ensifentrine's closest competitors are Symbicort marketed by AstraZeneca plc; Spiriva marketed by Boehringer Ingelheim GmbH; Advair and Breo marketed by GlaxoSmithKline plc; and Anoro marketed by GlaxoSmithKline. These products include various combinations of LABA bronchodilators, inhaled corticosteroids (ICS), and long-acting anti-muscarinic bronchodilators.
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Glaxosmithkline Plc's business model focuses on researching, developing, manufacturing, and marketing innovative healthcare products and medicines globally.
Intra Cellular Therapies Inc operates as a biopharmaceutical company that focuses on the discovery and development of innovative therapeutics for the treatment of neuropsychiatric and neurodegenerative diseases. Their business model involves conducting research and clinical trials to validate the efficacy and safety of their drug candidates. Once successful, they aim to gain regulatory approvals, form strategic partnerships, and commercialize their products to provide medical solutions for patients suffering from these challenging conditions.
Sources:
Verona Pharma Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Verona Pharma Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
